Showing results (1941-1950 of 2,088) with videos related to
Sort By:
Pageof 209
Zeitschrift Fur Gastroenterologie|November 19, 2019
[Current recommendations for surveillance, risk reduction and therapy in Lynch syndrome patients]Robert Hüneburg, Stefan Aretz, Reinhard Büttner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.JCO Oncology Practice|October 14, 2022
High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated CourseDarragh F O'Donoghue, Huong L Truong, Heidi D Finnes, et al.American Journal of Hematology|August 20, 2018
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.Hematological Oncology|October 7, 2025
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) CohortJames R Cerhan, Tereza Sokolova, Elliott J Cahn, et al.Blood Cancer Journal|July 12, 2025
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphomaJanek S Walker, Kerstin Wenzl, Joseph P Novak, et al.Blood Advances|January 11, 2024
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapyJessica F Burlile, Kelsey M Frechette, William G Breen, et al.Blood Cancer Journal|October 9, 2024
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomasMelissa A Hopper, Abigail R Dropik, Janek S Walker, et al.The Lancet. Haematology|March 31, 2022
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort studyCarla Casulo, Melissa C Larson, Julianne J Lunde, et al.Pageof 209